BeiGene, Ltd. Banner Image

BeiGene, Ltd.

  • Ticker BGNE
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
BeiGene, Ltd. Logo Image
  • 1001-5000 Employees
  • Based in Cambridge, Massachusetts
BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Their 4,200+ employees in China, the United States, Australia, Europe, and elsewhere are committed to expediting the development of a diverse pipeline of novel therapeuticsMore. They currently market two internally discovered oncology products: BTK inhibitor BRUKINSA® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. They also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma.
4.8 / 5.0 (117)

BeiGene, Ltd. reports have an aggregate usefulness score of 4.8 based on 117 reviews.

BeiGene, Ltd.

Most Recent Annual Report

BeiGene, Ltd.
MOST RECENT 2023 Annual Report and Form 10K

Older/Archived Annual Reports

BeiGene, Ltd. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!